Page 120 - Read Online

Best et al. Hepatoma Res 2020;6:62 I http://dx.doi.org/10.20517/2394-5079.2020.56 Page 11 of 13

11. Wang Y, Luo Q, Li Y, Deng S, Wei S, et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinomas: a meta-
analysis of randomized and nonrandomized controlled trials. PLoS One 2014;9:e84484.
12. Zheng SS, Xu X, Wu J, Chen J, Wang WL, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.
Transplantation 2008;85:1726-32.
13. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic
assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
14. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from
1975 to 2005. J Clin Oncol 2009;27:1485-91.
15. Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, et al. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche
Krebshilfe,AWMF): Diagnostik und Therapie des hepatozellulären Karzinoms, Kurzversion 1.0, AWMF Registrierungsnummer: 032-
053OL,2013. Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/HCC/S3-HCC-
OL-Langversion-V1.0.pdf. [Last accessed on 14 Aug 2020]
16. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
17. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;56:908-43.
18. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular
carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
19. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, et al. Asian pacific association for the study of the liver consensus
recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74.
20. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based
Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-64.
21. Bruix J, Sherman M, Practice Guidelines Committee AAftSoLD. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
22. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
23. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of
hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
24. Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a
multidisciplinary team. J Hepatol 2014;60:110-7.
25. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer
2009;115:5651-61.
26. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, et al. Surveillance imaging and alpha fetoprotein for early detection of
hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154:1706-18.e1.
27. Araujo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic
steatohepatitis: what we need in the future. Liver Int 2018;38 Suppl 1:47-51.
28. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
29. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and
non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
30. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients
with hepatocellular carcinoma in the U.S. Hepatology 2014;59:2188-95.
31. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, et al, Global Nonalcoholic Steatohepatitis Council. Nonalcoholic
steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol
2019;17:748-55.e3.
32. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, et al. Risk of hepatocellular cancer in patients with non-alcoholic
fatty liver disease. Gastroenterology 2018;155:1828-37.e2.
33. Weinmann A, Alt Y, Koch S, Nelles C, Duber C, et al. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular
carcinoma. BMC Cancer 2015;15:210.
34. Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer 1989;64:2117-20.
35. Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, et al. Serum alpha-fetoprotein levels in patients with advanced
hepatitis C: results from the HALT-C trial. J Hepatol 2005;43:434-41.
36. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and
prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
37. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 2001;313:15-9.
38. Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of
primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-31.
39. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma.
Hepatology 2012;55:483-90.
40. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for
preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-41.
41. Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS. Production of embryonal alpha-globulin by transplantable mouse
hepatomas. Transplantation 1963;1:174-80.
42. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma.